|
GTF2B expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.99460000025209E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.92710000000274E-05 |
| Normal-vs-Stage2 |
7.02300000376965E-08 |
| Normal-vs-Stage3 |
5.65690000398078E-08 |
| Normal-vs-Stage4 |
4.41289999997263E-06 |
| Stage1-vs-Stage2 |
1.057010E-03 |
| Stage1-vs-Stage3 |
1.446250E-02 |
| Stage1-vs-Stage4 |
6.857600E-02 |
| Stage2-vs-Stage3 |
1.332550E-01 |
| Stage2-vs-Stage4 |
1.797400E-01 |
| Stage3-vs-Stage4 |
9.846600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.48229999999516E-07 |
| Normal-vs-AfricanAmerican |
2.232400E-02 |
| Normal-vs-Asian |
4.181800E-03 |
| Caucasian-vs-AfricanAmerican |
5.219600E-01 |
| Caucasian-vs-Asian |
4.234200E-01 |
| AfricanAmerican-vs-Asian |
9.756800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.60919999991904E-07 |
| Normal-vs-Female |
4.20959999969384E-07 |
| Male-vs-Female |
3.207600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.804300E-03 |
| Normal-vs-Age(41-60Yrs) |
1.8342000029925E-08 |
| Normal-vs-Age(61-80Yrs) |
4.78920003654792E-09 |
| Normal-vs-Age(81-100Yrs) |
2.161900E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.203900E-03 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.31960000004927E-06 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.936200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.766400E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.856000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.799000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.539040E-01 |
| Classical-VS-Follicular |
7.76649999978396E-07 |
| Classical-VS-Other |
6.701800E-01 |
| Classical-VS-Normal |
3.443400E-04 |
| Tall-VS-Follicular |
1.335640E-01 |
| Tall-VS-Other |
7.767000E-01 |
| Tall-VS-Normal |
3.381900E-04 |
| Follicular-VS-Other |
2.898200E-01 |
| Follicular-VS-Normal |
1.58439994457638E-09 |
| Other-VS-Normal |
7.985700E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.72559982864118E-10 |
| Normal-vs-N1 |
3.955200E-04 |
| N0-vs-N1 |
1.665030E-01 |
|
|
